Abstracts Archive - Page 870 of 2425 - ACR Meeting Abstracts

Abstract Number: 1674 • 2019 ACR/ARP Annual Meeting
Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience
Victor Pimentel-Quiroz¹, Alfredo Sánchez-Torres ², Eduardo Acevedo-Vásquez ³, Rocío-V. Gamboa-Cárdenas ⁴, Cristina Reátegui-Sokolova ⁵, Mariela Medina-Chinchón ², Francisco Zevallos ⁵, Erika Noriega ⁴, José Alfaro-Lozano ⁴, Jorge Cucho-Venegas ², César Sánchez-Schwartz ², Zoila Rodríguez-Bellido ⁴, Risto Perich-Campos ⁴, Cesar Pastor-Asurza ⁵, Graciela Alarcón ⁶ and Manuel Ugarte-Gil ⁷, ¹Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ³Hospital Nacional “Guillermo Almenara Irigoyen” Essalud, Lima., Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶University of Alabama at Birmingham, Birmingham, ⁷Universidad Científica del Sur, Lima, Peru
Background/Purpose: To identify demographic and clinical risk factors for mortality in patients with ANCA-associated vasculitis (AAV) who were followed-up in a Latin-American Tertiary Referral Hospital.Methods:…
Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis
Liqin Wang¹, Eli Miloslavsky ², John Stone ³, Hyon K. Choi ⁴, Li Zhou ⁵ and Zachary Wallace ², ¹Brigham and Women's Hospital, Boston, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death. Retrospective studies on the clinical course of AAV, including the…
Abstract Number: 1676 • 2019 ACR/ARP Annual Meeting
Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?
Veena Patel¹ and Kim Trotter ¹, ¹University of Chicago, Chicago, IL
Background/Purpose: Patients with rheumatic diseases are often at risk for opportunistic infections given the combination of disease manifestations and immunosuppressive treatment regimens, but the rates…
Abstract Number: 1677 • 2019 ACR/ARP Annual Meeting
Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?
Pauline Morel ¹, Alexandre Karras ², Raphael Porcher ³, Xavier Belenfant ⁴, Vincent Audard ⁵, Cédric Rafat ⁶, Guillaume Hanouna ⁷, Séverine Beaudreuil ⁸, Cédric Vilain ⁹, Aurélie Hummel ¹⁰, Benjamin Terrier ¹¹, Evangeline Pillebout ¹², Matthieu Groh ¹³, Romain Jouenne ¹⁴, Robin Dhote ¹⁵, Olivier Fain ¹⁶, Matthieu Ponsoye ¹⁷, Nicolas Noel ¹⁸, Nicolas Limal ¹⁹, Loïc Guillevin ¹¹, Luc Mouthon ¹¹ and Alexis Régent¹¹, ¹Cochin Hospital, Paris, France, ²Paris HEGP, Paris, France, ³Hotel Dieu Hospital, Paris, France, ⁴Service de néphrologie, Hôpital André Grégoire, 56 Boulevard de la Boissière Montreuil, France, Montreuil, Ile-de-France, France, ⁵Henri Mondor Hospital, Créteil, France, ⁶Tenon Hospital, Paris, France, ⁷Service de néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France., Paris, Ile-de-France, France, ⁸Bicetre Hospital, Le Kremlin Bicetre, France, ⁹Service de néphrologie hémodialyse, Hôpital Ambroise Paré, APHP, 9 avenue Charles de Gaulle, Boulogne-Billancourt, France, Boulogne-Billancourt, Ile-de-France, France, ¹⁰APHP, Paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹²Service de néphrologie et transplantation, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France., Paris, Ile-de-France, France, ¹³Service de médecine interne, maladies systémiques, Hôpital Saint Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France, Paris, Ile-de-France, France, ¹⁴Service de médecine interne, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France, Paris, Ile-de-France, France, ¹⁵Service de médecine interne, Hôpital Avicenne, AP-PH, 125 rue de Stalingrad, Bobigny, France, Bobigny, Ile-de-France, France, ¹⁶Service de médecine interne, Hôpital Saint-Antoine, AP-HP, 184 rue du Faubourg Saint-Antoine, Paris, France, Paris, Ile-de-France, France, ¹⁷Service de médecine interne, Hopital Ambroise Paré, Boulogne-Billancourt, Boulogne-Billancourt, Ile-de-France, France, ¹⁸Service de médecine interne et immunologie clinique, Hôpital Bicêtre, AP-HP, 78 rue du Général Leclerc, Kremlin-Bicêtre, France, Kremil-Bicêtre, Ile-de-France, France, ¹⁹Service de médecine interne, Hôpital Henri-Mondor, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, France, Créteil, Ile-de-France, France
Background/Purpose: Induction therapy for severe ANCA-associated vasculitides (AAVs) is based on the combination of glucocorticoids and cyclophosphamide (CYC) or rituximab (RTX). For patients with severe…
Abstract Number: 1678 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis
Haidy Adel Youssef¹ and Mehrnaz Hojjati ², ¹Riverside Community Hospital/ UCR School of Medicine Internal Medicine Residency Program, Corona, CA, ²Department of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: ANCA associated vasculitis patients have a wide spectrum of pulmonary involvement in the form nodular disease (especially peri-bronchial nodules), cavitating lesions, diffuse alveolar hemorrhage and less…
Abstract Number: 1679 • 2019 ACR/ARP Annual Meeting
Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases are both forms of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Standard of…
Abstract Number: 1680 • 2019 ACR/ARP Annual Meeting
Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases to anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Standard of care (SOC)…
Abstract Number: 1681 • 2019 ACR/ARP Annual Meeting
The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)
Zachary Wallace¹, Xiaoqing Fu ¹, Yuqing Zhang ², John Stone ³ and Hyon K. Choi ², ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a small vessel vasculitis associated with an intense inflammatory state. AAV patients are at a 2-fold higher risk of cardiovascular…
Abstract Number: 1682 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Granulomatosis with polyangiitis (GPA, formerly known and Wegener’s granulomatosis) is a major subtype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by granulomatous inflammation of…
Abstract Number: 1683 • 2019 ACR/ARP Annual Meeting
Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort
Silvia Sartorelli ¹, Pascal Cohen ², Bertrand Dunogue ², Alexis Régent ², Xavier Puéchal for the French Vasculitis Study Group ², Luc Mouthon ², Loic Guillevin ² and Benjamin Terrier², ¹Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ²National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis characterized by blood and tissue eosinophilia, and asthma. Its cardiac involvement is a major…
Abstract Number: 1684 • 2019 ACR/ARP Annual Meeting
Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual
Paolo Delvino ¹, Federica Sardanelli ², Pascal Cohen ³, Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³, Loic Guillevin ³ and Benjamin Terrier³, ¹Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Vercelli, Italy, ²Department of Internal Medicine , Clinical Immunology Unit of Genoa and Policlinico San Martino, Genova, Italy, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) require glucocorticoids (GCs) and immunosuppressants (IS) to induce and maintain remission. At the era of highly…
Abstract Number: 1685 • 2019 ACR/ARP Annual Meeting
Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Due to the rarity of polyarteritis nodosa (PAN), no study has ever investigated inpatient characteristics, healthcare utilization and frequency of comorbidities of patients with…
Abstract Number: 1686 • 2019 ACR/ARP Annual Meeting
Risk of Vasculitis Associated with Inflammatory Bowel Diseases: Evidence for a Role of TNF-α Blockers
Benjamin Terrier¹, Laurent Beaugerie ², Philippe Seksik ², Harry Sokol ² and Julien Kirchgesner ², ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²Saint-Antoine Hospital, Paris, France
Background/Purpose: An increased risk of side effects, especially infections, has been reported among patients receiving tumor necrosis factor (TNF)-α blockers. Some leukocytoclastic cutaneous vasculitides reportedly occurred…
Abstract Number: 1687 • 2019 ACR/ARP Annual Meeting
Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis
Thomas Bettuzzi ¹, Alban Deroux ², Marie Jachiet ³, Meryem-Maud Farhat ⁴, Julien Wipff ¹, Marc Fabre ⁵, Laurence Bouillet ², Nora Kramkimel ¹, Selim Aractingi ¹, Nicolas Dupin ¹ and Benjamin Terrier⁶, ¹Cochin Hospital, Paris, France, ²CHU, Grenoble, France, ³Saint Louis Hospital, Paris, France, ⁴CHRU, Lille, France, ⁵CH, Bourgoin-Jailleu, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Urticarial vasculitis (UV) is a rare disease characterized by dermal capillary inflammation responsible for long-lasting urticarial lesions. UV can be separated into 2 different…
Abstract Number: 1688 • 2019 ACR/ARP Annual Meeting
Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
Benjamin Terrier¹, Jonathan London ², Fabrice Bonnet ³, Diane Cerutti ⁴, Nathalie Costedoat-Chalumeau ⁵, Elisabeth Diot ⁶, Yasmina Ferfar ⁷, Aurélie Hummel ⁸, Gilles Kaplanski ⁹, Isabelle Marie ¹⁰, Thomas Quémeneur ¹¹, Patricia Rullier ¹², Patricia Senet ¹³, Noémie Le Gouellec ¹⁴, Julie Lejeune ⁷, David Saadoun ¹⁵ and Patrice Cacoub ¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²Croix Saint-Simon Hospital, Paris, France, ³CHU, Bordeaux, France, ⁴CH, Toulon, France, ⁵Cochin University Hospital, Paris, France, ⁶APHP, Tours, France, ⁷Pitié-Salpétrière Hospital, Paris, France, ⁸APHP, Paris, France, ⁹CHU, Marseille, France, ¹⁰CHU, Rouen, France, ¹¹CH Valenciennes, Valenciennes, France, ¹²CHU, Montpellier, France, ¹³Tenon Hospital, Paris, France, ¹⁴CH, Valenciennes, France, ¹⁵AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: A previous retrospective study suggested superiority of glucocorticoids (GCs) plus rituximab (RTX) compared to GCs alone to induce complete clinical response in non-infectious cryoglobulinemia…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].